132 related articles for article (PubMed ID: 34765196)
1. A case of papillary hyperplasia of thyroid misdiagnosed as papillary thyroid carcinoma: Case report and review of literature.
Alharbi SF; Abba AA; Hafiz AA; Abdulhalim AM; Bokhari GY; Esheba GE
Clin Case Rep; 2021 Nov; 9(11):e04867. PubMed ID: 34765196
[TBL] [Abstract][Full Text] [Related]
2. A potential biomarker hsa-miR-200a-5p distinguishing between benign thyroid tumors with papillary hyperplasia and papillary thyroid carcinoma.
Wang X; Huang S; Li X; Jiang D; Yu H; Wu Q; Gao C; Wu Z
PLoS One; 2018; 13(7):e0200290. PubMed ID: 30005075
[TBL] [Abstract][Full Text] [Related]
3. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.
Ma H; Yan J; Zhang C; Qin S; Qin L; Liu L; Wang X; Li N
Int J Clin Exp Pathol; 2014; 7(11):7999-8007. PubMed ID: 25550843
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
5. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
Tong J; Wang Y; Da JP
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma.
Huang L; Wang X; Huang X; Gui H; Li Y; Chen Q; Liu D; Liu L
Oncol Lett; 2018 Apr; 15(4):4269-4277. PubMed ID: 29541194
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of CK19 and galectin-3 in differentiating papillary thyroid carcinoma from nonneoplastic lesions of thyroid.
Prasad PA; Raju K
J Cancer Res Ther; 2022; 18(3):644-649. PubMed ID: 35900535
[TBL] [Abstract][Full Text] [Related]
8. [Thyroid papillary hyperplasia mistaken for papillary carcinoma in fine needle aspiration cytology and frozen section examination].
Flikweert ER; Nugteren WA; Groote AD
Ned Tijdschr Geneeskd; 2003 Mar; 147(11):510-3. PubMed ID: 12677951
[TBL] [Abstract][Full Text] [Related]
9. The value of tumor markers in the diagnosis of papillary thyroid carcinoma alone and in combination.
Ma H; Xu S; Yan J; Zhang C; Qin S; Wang X; Li N
Pol J Pathol; 2014 Oct; 65(3):202-9. PubMed ID: 25372417
[TBL] [Abstract][Full Text] [Related]
10. Extremely Well-Differentiated Papillary Thyroid Carcinoma Resembling Adenomatous Hyperplasia Can Metastasize to the Skull: A Case Report.
Pyo JY; Kim J; Choi SE; Shin E; Yang SW; Park CS; Kim SM; Hong S
Yonsei Med J; 2017 Jan; 58(1):255-258. PubMed ID: 27873522
[TBL] [Abstract][Full Text] [Related]
11. Expressions of D2-40, CK19, galectin-3, VEGF and EGFR in papillary thyroid carcinoma.
Gong L; Chen P; Liu X; Han Y; Zhou Y; Zhang W; Li H; Li C; Xie J
Gland Surg; 2012 May; 1(1):25-32. PubMed ID: 25083424
[TBL] [Abstract][Full Text] [Related]
12. Papillary carcinoma of the thyroid: can operative management be based solely on fine-needle aspiration?
Chen H; Zeiger MA; Clark DP; Westra WH; Udelsman R
J Am Coll Surg; 1997 Jun; 184(6):605-10. PubMed ID: 9179117
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China.
Song Q; Wang D; Lou Y; Li C; Fang C; He X; Li J
Diagn Pathol; 2011 Dec; 6():126. PubMed ID: 22188859
[TBL] [Abstract][Full Text] [Related]
14. Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.
Dunđerović D; Lipkovski JM; Boričic I; Soldatović I; Božic V; Cvejić D; Tatić S
Diagn Pathol; 2015 Oct; 10():196. PubMed ID: 26503236
[TBL] [Abstract][Full Text] [Related]
15. CD56, CD57, HBME1, CK19, Galectin-3 and p63 immunohistochemical stains in differentiating diagnosis of thyroid benign/malign lesions and NIFTP.
Tastekin E; Keskin E; Can N; Canberk S; Mut A; Erdogan E; Asa N; Güldiken S; Sezer A; Azatcam M
Pol J Pathol; 2019; 70(4):286-294. PubMed ID: 32146798
[TBL] [Abstract][Full Text] [Related]
16. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid.
El Demellawy D; Nasr A; Alowami S
Diagn Pathol; 2008 Feb; 3():5. PubMed ID: 18254952
[TBL] [Abstract][Full Text] [Related]
17. Medullary thyroid carcinoma combined with papillary thyroid carcinoma: case report and literature review.
Yao J; Li CF; Wang JJ; Zhang SY; Li YL; Yang J; Zheng H
Int J Clin Exp Pathol; 2020; 13(10):2710-2717. PubMed ID: 33165348
[TBL] [Abstract][Full Text] [Related]
18. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.
Casey MB; Lohse CM; Lloyd RV
Endocr Pathol; 2003; 14(1):55-60. PubMed ID: 12746563
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
20. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
